Pace Life Sciences Expands Salem Facility with New Aseptic Fill-Finish Center of Excellence
Key Insights
Pace Life Sciences (search) has remodeled and expanded its Salem, New Hampshire facility to establish a Center of Excellence for Aseptic Fill-Finish Processing, enhancing capabilities for both small and large molecule manufacturing.
The expansion includes an isolated vial filling line designed for smaller batch manufacturing with high sterility assurance and EU Annex 1 compliance, targeting vaccines (search), gene therapies (search), antibodies (search), and protein-based therapeutics (search).
The company will host a grand opening ceremony on July 16, 2025, showcasing its enhanced cGMP manufacturing capabilities for injectable products in response to growing demand in biologics (search) and large molecule products.
Pace Life Sciences (search) LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO), has completed a significant expansion of its Salem, New Hampshire facility to establish a Center of Excellence for Aseptic Fill-Finish Processing. The enhanced facility positions the company to better serve the growing demand for sterile manufacturing services across vaccines (search), gene therapies (search), antibodies (search), and protein-based therapeutics (search).
Enhanced Manufacturing Capabilities
The expansion centers on the addition of an isolated vial filling line specifically designed to facilitate smaller batch size manufacturing while maintaining high sterility assurance and EU Annex 1 compliance. This new capability allows Pace to serve clients requiring cGMP manufacturing in the injectable space for a diverse range of therapeutic products.
"Through our continuous improvement initiatives at Pace Life Sciences (search), our team recognized an opportunity to enhance and expand our capabilities in response to our past success in partnering with clients on small molecule fill-finish programs and the increasing demand for fill-finish manufacturing generated by growth in biologics (search) and other large molecule products," stated Dawn Von Rohr, President of Pace Life Sciences.
Strategic Response to Market Demand
The facility enhancement represents Pace's strategic response to the evolving pharmaceutical landscape, particularly the increasing demand for biologics (search) and large molecule manufacturing services. The company's investment in state-of-the-art technology ensures scalability alongside client program evolution and advancing regulatory expectations.
Von Rohr emphasized the facility's role in client partnerships: "The remodel of our state-of-the-art facility in Salem, NH, ensures that we can scale alongside our clients as their programs evolve and regulatory expectations advance."
Industry Showcase Event
Pace Life Sciences (search) will host a grand opening ceremony and open house on July 16, 2025, at 13 Industrial Way, Salem, NH. The event, scheduled from 12:30 to 4 PM ET, will feature guided facility tours with the technical team, showcasing the company's cutting-edge manufacturing technology and providing networking opportunities with industry experts and Pace Life Sciences professionals.
The expansion reinforces Pace Life Sciences (search)' position as a comprehensive CRDMO serving the pharmaceutical and biotechnology industries, with enhanced capabilities spanning from small molecule fill-finish programs to complex biologics (search) manufacturing.